ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are shooting up almost 17% with investors clearly paying keen attention to the biotech firm’s Parkinson’s Disease Psychosis …
Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …
Dynavax Technologies Corporation (NASDAQ:DVAX) shares are skyrocketing over 70% after the FDA VRBPAC panel voted 12-1 with 3 abstentions that the safety to …
The FDA Vaccines & Related Biological Products Advisory Committee (VRBPAC) is meeting today to discuss the safety and efficacy of Dynavax Technologies Corporation’s (NASDAQ:DVAX) experimental …
Gilead Sciences, Inc. Cowen analyst Phil Nadeau is out with a research note on shares of Gilead Sciences, Inc.
Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc …
Yesterday at the 9th International Aids Society (IAS) conference on HIV Science in Paris, Gilead Sciences, Inc. (NASDAQ:GILD) made crucial strides forward.
Cowen analyst Phil Nadeau is out with a bullish note on shares of Genocea Biosciences Inc (NASDAQ:GNCA), reiterating an Outperform rating with a $40 price …
Third party sources are saying Gilead Sciences, Inc. (NASDAQ:GILD) domestic Wholesale Acquisition Costs (WACs) of various products have seen a price boost, to …
Gilead Sciences, Inc. (NASDAQ:GILD) impressed Cowen analyst Phil Nadeau with its successful four Phase III trials evaluating a dose combination of the biotech …
